A look into Pfizer Inc. (PFE)’s deeper side

Pfizer Inc. (NYSE: PFE) stock jumped 1.48% on Friday to $44.57 against a previous-day closing price of $43.92. With 18.48 million shares changed hands, the volume of the stock remained heavier than its average volume of 17.86 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $45.00 whereas the lowest price it dropped to was $43.52. The 52-week range on PFE shows that it touched its highest point at $61.71 and its lowest point at $40.94 during that stretch. It currently has a 1-year price target of $57.01. With its current market cap of 249.65 billion, PFE has annualized dividend of $1.60 while the current yield stands at 3.59%. Beta for the stock currently stands at 0.69.

Top 5 Tech Stocks Every Investor Should Buy Right Now

While finding excellent stocks with the potential for gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Tech Stocks Every Investor Should Buy Right Now", we have identified five tech stocks we believe could appreciate.

Sign up here to get your free report now.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PFE was down-trending over the past week, with a drop of -2.98%, but this was down by -7.17% over a month. Three-month performance dropped to -11.02% while six-month performance fell -14.60%. The stock gained 1.41% in the past year, while it has lost -24.52% so far this year. A look at the trailing 12-month EPS for PFE yields 5.19 with Next year EPS estimates of 5.24. For the next quarter, that number is 1.50. This implies an EPS growth rate of 233.60% for this year and -19.22% for next year. EPS is expected to decline by -1.20% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 27.40%.

Float and Shares Shorts:

At present, 5.61 billion PFE shares are outstanding with a float of 5.61 billion shares on hand for trading. On Aug 30, 2022, short shares totaled 62.2 million, which was 1.11% higher than short shares on Jul 28, 2022. In addition to Dr. Albert Bourla D.V.M., DVM, Ph.D. as the firm’s Chairman & CEO, Mr. Frank A. D’Amelio serves as its CFO & Exec. VP.

Institutional Ownership:

Through their ownership of 70.21% of PFE’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 40.36% of PFE, in contrast to 29.64% held by mutual funds. Shares owned by individuals account for 0.30%. As the largest shareholder in PFE with 8.29% of the stake, The Vanguard Group, Inc. holds 465,062,213 shares worth 465,062,213. A second-largest stockholder of PFE, SSgA Funds Management, Inc., holds 287,217,028 shares, controlling over 5.12% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in PFE, holding 284,350,631 shares or 5.07% stake. With a 2.96% stake in PFE, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 166,147,649 shares are owned by the mutual fund manager. The Vanguard 500 Index Fund, which owns about 2.23% of PFE stock, is the second-largest Mutual Fund holder. It holds 125,220,047 shares valued at 5.66 billion. Washington Mutual Investors Fund holds 1.36% of the stake in PFE, owning 76,025,842 shares worth 3.44 billion.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jul 02, 2022, PFE reported revenue of $27.74B and operating income of $12.41B. It generated $9.91B net income for the quarter, which came to $29.31B over the last twelve months. The EBITDA in the recently reported quarter was $13.66B and diluted EPS was $1.73. EBITDA for the full year was $40.97B.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PFE since 23 analysts follow the stock currently. There are 10 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 13 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PFE analysts setting a high price target of $75.00 and a low target of $44.00, the average target price over the next 12 months is $55.88. Based on these targets, PFE could surge 68.27% to reach the target high and fall by -1.28% to reach the target low. Reaching the average price target will result in a growth of 25.38% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. PFE will report FY 2022 earnings on 01/31/2023. Analysts have provided yearly estimates in a range of $6.90 being high and $6.30 being low. For PFE, this leads to a yearly average estimate of $6.50. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Pfizer Inc. surprised analysts by $0.32 when it reported $2.04 EPS against a consensus estimate of $1.72. The surprise factor in the prior quarter was $0.13. Based on analyst estimates, the high estimate for the next quarter is $2.00 and the low estimate is $1.19. The average estimate for the next quarter is thus $1.50.

Summary of Insider Activity:

Insiders traded PFE stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 28 while that of sell transactions has risen to 114 over the past year. The total number of shares bought during that period was 1,499,101 while 1,227,447 shares were sold.

Leave a Comment

Your email address will not be published.